

Personal Information

Email: faysal.dane@marmara.edu.tr

Web: <https://avesis.marmara.edu.tr/faysal.dane>

Advising Theses

DANE F., Mide kanserinde reg1 alfa proteini sıklığı ve klinikopatolojik bulgularla ilişkisi, M.Kanitez(Student), 2013

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma**
Basoglu T., Babacan N. A., Ozturk F. E., ARIKAN R., DEMİRCAN N., Telli T. A., Ercelep O., DANE F., Yumuk P. F.
Indian Journal of Cancer, vol.60, no.2, pp.179-184, 2023 (SCI-Expanded)
- II. **Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment**
AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S., Sariyar N., Isik S., Arikan R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., et al.
ANNALS OF NUCLEAR MEDICINE, vol.36, no.11, pp.964-975, 2022 (SCI-Expanded)
- III. **Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey**
ÖZET A., DANE F., Aykan N. F., YALÇIN Ş., EVRENSEL T., ÖZKAN M., Karabulut B., Ormeci M. N., Atasev O., Vidot L., et al.
FUTURE ONCOLOGY, vol.18, no.29, pp.3267-3276, 2022 (SCI-Expanded)
- IV. **Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy**
AKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., BAŞOĞLU TÜYLÜ T., Kaya S., Ercelep O., Babacan N. A., et al.
FUTURE ONCOLOGY, vol.18, pp.2425-2439, 2022 (SCI-Expanded)
- V. **First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis**
Isikdogan A., Turk H., Bilir C., Sendur M., Karabulut B., Artac M., Cicin I., Geredeli C., Alacacioglu A., Kefeli U., et al.
ANNALS OF ONCOLOGY, vol.33, 2022 (SCI-Expanded)
- VI. **Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study**
Artac M., Cubukcu E., Bozkurt O., Bilici A., Celik S., Ozcelik M., Oven B., Simsek E., Geredeli C., Karaca M., et al.
ANNALS OF ONCOLOGY, vol.33, 2022 (SCI-Expanded)
- VII. **Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study**
YASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E., et al.
FUTURE ONCOLOGY, vol.18, pp.1235-1244, 2022 (SCI-Expanded)
- VIII. **Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in**

Resected Pancreatic Adenocarcinoma

BAŞOĞLU TÜYLÜ T., AKAR K. E., BAĞCI ÇULÇI P., Babacan N. A., ÖZTÜRK M. A., ÖZTÜRK F. E., DEMİRCAN N. C., Arikan R., AKIN TELLİ T., Ercelepl O., et al.

BALKAN MEDICAL JOURNAL, vol.39, no.1, pp.12-20, 2022 (SCI-Expanded)

- IX. **Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma**
AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., Yasar A., Majidova N., Celebi A., EROL B., et al.
Nutrition and Cancer, vol.74, no.7, pp.2499-2507, 2022 (SCI-Expanded)
- X. **Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study**
BENEKLİ M., Gumus M., ÖZKAN M., DANE F., ELKIRAN E. T., ÇİÇİN İ., Sevinc A., Aliustaoglu M., Isikdogan A., Meydan N., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.7, pp.1623-1630, 2021 (SCI-Expanded)
- XI. **A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study**
Abali H., YALÇIN Ş., Onal H. C., DANE F., Oksuzoglu B., ÖZDEMİR N., Mertsoylu H., ARTAÇ M., Camci C., KARABULUT B., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.44, no.7, pp.301-307, 2021 (SCI-Expanded)
- XII. **The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study**
Akdeniz N., Kaplan M. A., Uncu D., İNANÇ M., Kaya S., DANE F., KÜÇÜKÖNER M., Demirci A., BİLİCİ M., Durnali A. G., et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.36, no.6, pp.1311-1319, 2021 (SCI-Expanded)
- XIII. **Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma**
Ercelep O., Alan O., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Simsek E. T., Babacan N. A., Kaya S., DANE F., et al.
TUMORI J, vol.107, no.3, pp.231-237, 2021 (SCI-Expanded)
- XIV. **Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.**
Kefeli U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., Cubukcu E., Cicin I., Yalcin S., Turk H. M., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- XV. **Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study**
Koca S., Besiroglu M., Ozcelik M., Karaca M., BİLİCİ M., Hacioglu B., DOĞU G. G., Kaplan N. B., Oruc Z., Aydin D., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.3, pp.541-546, 2021 (SCI-Expanded)
- XVI. **Clinicopathologic Features of Large Cell Neuroendocrine Carcinoma of Lung**
Arikan R., Demircan N., Basoglu T., Telli T. A., Ercelep O., Dane F., Yumuk P. F.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.3, 2021 (SCI-Expanded)
- XVII. **Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience**
Alan O., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Ercelep O., Kaya S., Babacan N. A., ATASOY B. M., BOZKURT S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.2, pp.329-339, 2021 (SCI-Expanded)
- XVIII. **Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches**
Karaca B. S., Sezer A., Goksu S. S., ÇİÇİN İ., Erdem D., ÇUBUKÇU E., DANE F., Hacibekiroglu I., Oksuzoglu B., Alnigenis E., et al.
JOURNAL OF TRANSLATIONAL MEDICINE, vol.19, 2021 (SCI-Expanded)

- XIX. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer**
Demirelli B., Babacan N. A., Ercelep O., Ozturk M. A., Kaya S., Tanrikulu E., Khalil S., Hasanov R., Alan O., AKIN TELLİ T., et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.2, pp.230-238, 2021 (SCI-Expanded)
- XX. A rare case of gastric cancer with bilateral breast metastasis during pregnancy**
Başoğlu Tüylü T., Akın Telli T., Demircan N. C., Arikan R., Ercelep O., Özgüven S., Soysal S., Memişoğlu A., Dane F., Yumuk P. F.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.1, pp.220-226, 2021 (SCI-Expanded)
- XXI. QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer**
DEMİRCAN N. C., Akın Telli T., BAŞOĞLU TÜYLÜ T., Arikan R., Kocakaya D., Şahin A. A., Ercelep Ö., DANE F., YUMUK P. F.
CURRENT PROBLEMS IN CANCER, vol.44, no.6, 2020 (SCI-Expanded)
- XXII. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?**
Alan O., AKIN TELLİ T., Aktas B., KOCA S., ÖKTEN İ. N., Hasanov R., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Ercelep O., et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY, vol.18, no.1, 2020 (SCI-Expanded)
- XXIII. Long-term neuromusculoskeletal side effects and quality of life in nasopharyngeal cancer patients receiving radiochemotherapy**
ÜÇÜNCÜ KEFELİ A., ŞANAL TOPRAK C., Asedov R., Ozen Z., Akyuz G., DANE F., ATASOY B. M.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.277, no.8, pp.2325-2333, 2020 (SCI-Expanded)
- XXIV. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study**
YALÇIN Ş., DANE F., Oksuzoglu B., Ozdemir N. Y., Isikdogan A., ÖZKAN M., Demirag G. G., COŞKUN H. Ş., KARABULUT B., EVRENSEL T., et al.
BMC CANCER, vol.20, no.1, 2020 (SCI-Expanded)
- XXV. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study**
DANE F., Ozgurdal K., YALÇIN Ş., BENEKLİ M., Aykan N. F., YÜCEL İ., ÖZKAN M., EVRENSEL T., Sevinc A., COŞKUN H. Ş., et al.
BMJ OPEN, vol.10, no.3, 2020 (SCI-Expanded)
- XXVI. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy**
DEMİRCAN N. C., DANE F., Ozturk M. A., Babacan N. A., Besiroglu M., Kaya S., Ercelep O., Tanrikulu E., Halil S., Koca S., et al.
JOURNAL OF BUON, vol.24, no.4, pp.1494-1500, 2019 (SCI-Expanded)
- XXVII. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer**
Ercelep O., Alan O., Sahin D., Telli T. A., Salva H., Tuylu T. B., Babacan N. A., Kaya S., Dane F., Ones T., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY, vol.21, no.4, pp.499-504, 2019 (SCI-Expanded)
- XXVIII. Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study**
Demirci A., Alkis N., DANE F., Durnali A., Yazici O. K., Rzayev R., Kaya S., Yazilitas D., İNANÇ M., Ozcelik M., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.14, no.2, 2018 (SCI-Expanded)
- XXIX. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia**

Sevinc A, ÖZKAN M., Ozet A., DANE F., Oksuzoglu B., Isikdogan A., ÖZDEMİR F., Uncu D., GÜMÜŞ M., EVRENSEL T., et al.

ONCOTARGETS AND THERAPY, vol.11, pp.419-426, 2018 (SCI-Expanded)

- XXX. **A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study**

YALÇIN Ş., Yildiz R., DANE F., Karaoglu A., Oksuzoglu B., ÖZYILKAN Ö., Sevinc A., ÖZDEMİR F., Turna H., Uslu R., et al.
ONCOTARGETS AND THERAPY, vol.11, pp.1223-1228, 2018 (SCI-Expanded)

- XXXI. **EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry**

Gumus M., Ozkan M., Yilmaz U., Tekin S. B., Demir C., Erdogan A., Dane F.
JOURNAL OF THORACIC ONCOLOGY, vol.12, no.11, 2017 (SCI-Expanded)

- XXXII. **Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer**

Kaya S., Aktas B., Sismek E. T., Ozturk M. A., DEDE F., KAYA H., Ugurlu U., Ozgen Z., Koca S., Halil S., et al.
JOURNAL OF BUON, vol.22, no.5, pp.1191-1198, 2017 (SCI-Expanded)

- XXXIII. **Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less**

Ozaslan E., Karaca H., Koca S., Sevinc A., Hacioglu B., ÖZKAN M., Ozcelik M., Duran A. O., Hacibekiroglu I., Yildiz Y., et al.
ANTI-CANCER DRUGS, vol.28, no.2, pp.222-229, 2017 (SCI-Expanded)

- XXXIV. **Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life**

Abunahlah N., SANCAR M., DANE F., Ozyavuz M. K.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol.38, no.6, pp.1464-1476, 2016 (SCI-Expanded)

- XXXV. **Determination of potentially drug-drug interaction in oncology patients**

Abunahlah N., Sancar M., Dane F., Ozyavuz M. K., Izzettin F.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol.38, no.2, pp.504, 2016 (SCI-Expanded)

- XXXVI. **Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer**

Dinc N. S., Aydin K., Odabas H., Ercelep O., Tufan G., Seker M., Yasar N., Aydin D., Yuksel S., Mert A., et al.
ONCOLOGY RESEARCH AND TREATMENT, vol.39, no.3, pp.130-134, 2016 (SCI-Expanded)

- XXXVII. **Multicenter experience of adult medulloblastoma: A study of Anatolian Society of Medical Oncology (ASMO)**

Esbah O., Demirci U., DANE F., Gunaydsin Y., Ozdemir N., Ekinci A. S., Kodaz H., Yazilitas D., Rzayev R., Guney Y., et al.
JOURNAL OF BUON, vol.21, no.2, pp.456-460, 2016 (SCI-Expanded)

- XXXVIII. **Functional and clinical evaluation of renal injury in patients treated with adjuvant chemoradiotherapy for gastric cancer: Low dose and comorbidity considerations**

Ibrahimov R., ATASOY B. M., DEDE F., ARIKAN H., Ozen Z., Ozgen Z., DANE F., Abacioglu U.
JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, vol.9, no.1, pp.63-67, 2016 (SCI-Expanded)

- XXXIX. **Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors**

ARAS M., ERDİL T. Y., DANE F., Gungor S., ÖNEŞ T., DEDE F., İNANIR S., TUROĞLU H. T.
NUCLEAR MEDICINE COMMUNICATIONS, vol.37, no.1, pp.9-15, 2016 (SCI-Expanded)

- XL. **Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology**

Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S., et al.
TUMOR BIOLOGY, vol.36, no.12, pp.9641-9648, 2015 (SCI-Expanded)

- XLI. **Carbon-14 urea breath test: does it work in patients with partial gastric resection?**

DEDE F., Civen H., DANE F., Aliustaoglu M., Turhal S., TUROĞLU H. T., İNANIR S.
ANNALS OF NUCLEAR MEDICINE, vol.29, no.9, pp.786-791, 2015 (SCI-Expanded)

- XLII. **Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers**

Baykara M., BENEKLİ M., Ekinci O., Irkkan S. C., Karaca H., Demirci U., AKINCI M. B., Unal O. U., DANE F., Turkoz F. P.,

et al.

JOURNAL OF GASTROINTESTINAL SURGERY, vol.19, no.9, pp.1565-1571, 2015 (SCI-Expanded)

- XLIII. **Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma**

Turan N., BENEKLİ M., Unal O. U., Unek I. T., Tastekin D., DANE F., Algin E., Ulger S., Eren T., Topcu T. O., et al.

CHINESE JOURNAL OF CANCER RESEARCH, vol.27, no.4, pp.408-416, 2015 (SCI-Expanded)

- XLIV. **Radiation-induced oxidative injury of the ileum and colon is alleviated by glucagon-like peptide-1 and -2**

Deniz M., ATASOY B. M., DANE F., CAN G., ERZİK C., ÇETİNEL Ş., YEGEN B.

JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, vol.8, no.2, pp.234-242, 2015 (SCI-Expanded)

- XLV. **Is Perineural Invasio (PN) a Determinant of Disease Free Survival in Early Stage Colorectal Cancer?**

Ozturk M. A., DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., Buyukunal E., ÖZGÜROĞLU M., Turna H., Erdamar S., et al.

HEPATO-GASTROENTEROLOGY, vol.62, no.137, pp.59-64, 2015 (SCI-Expanded)

- XLVI. **Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study**

Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F., Reichardt P., Pimentel F. L., Cohn A., Follana P., et al.

ANNALS OF ONCOLOGY, vol.26, no.1, pp.149-156, 2015 (SCI-Expanded)

- XLVII. **Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)**

Cetin B., BENEKLİ M., Turker I., Koral L., Ulas A., DANE F., Oksuzoglu B., Kaplan M. A., Koca D., Boruban C., et al.

JOURNAL OF CHEMOTHERAPY, vol.26, no.5, pp.300-305, 2014 (SCI-Expanded)

- XLVIII. **Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer**

Turan N., BENEKLİ M., DANE F., Unal O. U., Kara H. V., Koca D., Balvan O., Eren T., Tastekin D., Helvacı K., et al.

THORACIC CANCER, vol.5, no.5, pp.398-404, 2014 (SCI-Expanded)

- XLIX. **Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology**

Demirci U., Coskun U., Karaca H., DANE F., Ozdemir N. Y., Ulas A., Baykara M., BENEKLİ M., ÖZKAN M., Buyukberber S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.4, pp.1581-1584, 2014 (SCI-Expanded)

- L. **Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients**

Atasoy B. M., Dane F., Cetin I. A., Ozgen Z., Kefeli A. U., Ibrahimov R., Turhal N. S., Abacioglu U., Turkeri L.

Clinical and Translational Oncology, vol.16, no.1, pp.91-95, 2014 (SCI-Expanded)

- LI. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**

Cabuk D., Basaran G., Teomete M., DANE F., Korkmaz T., Seber S., Telli F., YUMUK P. F., Turhal S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.1, pp.117-122, 2014 (SCI-Expanded)

- LII. **Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer**

Iyikesici M. S., BAŞARAN G., DANE F., Ekenel M., YUMUK P. F., ÇABUK D., Teomete M., Turhal N. S.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.7, no.5, pp.1459-1464, 2014 (SCI-Expanded)

- LIII. **Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology**

Gumusay O., Coskun U., Akman T., Ekinici A. S., Kocar M., Erceleb O. B., Yazici O., Kaplan M. A., Berk V., Cetin B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.140, no.1, pp.151-157, 2014 (SCI-Expanded)

- LIV. **XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology**

Duran A. O., Karaca H., Besiroglu M., Bayoglu I. V., Menekse S., Yapici H. S., Yazilitas D., Bahceci A., UYSAL M., Sevinc A., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.23, pp.10375-10379, 2014 (SCI-Expanded)

LV. Analysis of Resected Gastric Cancer in Turkish Population

Demir G., Unsal D., Zengin N., Er O., DANE F., YALÇIN Ş.

HEPATO-GASTROENTEROLOGY, vol.61, no.129, pp.259-266, 2014 (SCI-Expanded)

LVI. Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers

Cihan S., KÜÇÜKÖNER M., ÖZDEMİR N., DANE F., ŞENDUR M. A. N., Yazilitas D., Urakci Z., Durnali A., Yuksel S., AKSOY S., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.13, pp.5337-5341, 2014 (SCI-Expanded)

LVII. IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)

Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.8, 2013 (SCI-Expanded)

LVIII. COULD PRETREATMENT PET-CT STANDART UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO TREATMENT AND THE SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?

Aydin K., Odabas H., Seker M., Korkmaz T., Yasar N., Sener N., Aydin D., Ercelep O., Yuksel S., Mert A. G., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.8, 2013 (SCI-Expanded)

LIX. IS PET/CT A BETTER TOOL THAN CT IN RESPONSE EVALUATION AND FOLLOW-UP OF STAGE III NON-SMALL CELL LUNG CANCER AFTER CHEMORADIOOTHERAPY?

YUMUK P. F., Besiroglu M., DANE F., Kanitez M., Aktas B., Caglar H., YILDIZELİ B., DEDE F., Atasoy B., Turhal N. S.

JOURNAL OF THORACIC ONCOLOGY, vol.8, 2013 (SCI-Expanded)

LX. The First Metronidazole-Resistant Bacteroides Species Isolated at Marmara University Hospital: Bacteroides thetaiotaomicron

Toprak Ülger N., Sayin E., DANE F., Soyletir G.

MIKROBİYOLOJİ BÜLTENİ, vol.47, no.4, pp.717-721, 2013 (SCI-Expanded)

LXI. [The first metronidazole-resistant Bacteroides species isolated at Marmara University Hospital: Bacteroides thetaiotaomicron].

Toprak Ülger N., Sayin E., Dane F., Söyletir G.

Mikrobiyoloji bulteni, vol.47, no.4, pp.717-21, 2013 (SCI-Expanded)

LXII. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience

Kefeli U., BENEKLİ M., Sevinc A., Yildiz R., Kaplan M. A., Ciltas A., Balakan O., Isikdogan A., Coskun U., DANE F., et al.

ONCOLOGY LETTERS, vol.6, no.2, pp.605-611, 2013 (SCI-Expanded)

LXIII. The benefit of whole brain reirradiation in patients with multiple brain metastases

Ozgen Z., Atasoy B. M., Kefeli A. U., Seker A., Dane F., Abacioglu U.

Radiation Oncology, vol.8, no.1, 2013 (SCI-Expanded)

LXIV. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers

Baykara M., Buyukberber S., Ozturk B., Coskun U., Kaplan M. A., Unsal D. K., DANE F., Demirci U., BORA H., BENEKLİ M.

TUMORI, vol.99, no.4, pp.469-473, 2013 (SCI-Expanded)

LXV. Efficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experience

Kefeli U., Buyukberber S., Akyol M., Yildiz R., Kaplan M. A., Ciltas A., Sevinc A., Karaca H., Seker M., Ozdemir N., et al.

HEPATO-GASTROENTEROLOGY, vol.60, no.124, pp.647-652, 2013 (SCI-Expanded)

LXVI. Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey

Seker M., Sevinc A., Yildiz R., Cihan S., Kaplan M. A., Gokdurnali A., DANE F., Yaman E., Karaca H., Colak D., et al.

HEPATO-GASTROENTEROLOGY, vol.60, no.124, pp.768-775, 2013 (SCI-Expanded)

- LXVII. Health-related quality of life during postoperative chemoradiotherapy with oral uracil-tegafur and leucovorin in rectal cancer patients**
Ozgen Z., Ozden S., Dane F., Atasoy B. M., Akgunt Z., Yumuk P. F., Mayadagli A., Turhal N. S., Abacioglu U.
Hepato-Gastroenterology, vol.60, no.123, pp.533-537, 2013 (SCI-Expanded)
- LXVIII. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)**
Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., ENGİN H., Kaplan M. A., Gunaydin Y., Ozdemir N. Y., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.5, pp.829-835, 2013 (SCI-Expanded)
- LXIX. Childhood, Adolescents, and Young Adults (≤ 25 y) Colorectal Cancer: Study of Anatolian Society of Medical Oncology**
Kaplan M. A., Isikdogan A., Gumus M., Arslan U. Y., Geredeli C., Ozdemir N., Koca D., DANE F., Suner A., Elkiran E. T., et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.35, no.2, pp.83-89, 2013 (SCI-Expanded)
- LXX. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**
Korkmaz T., Seber S., Okutur K., Basaran G., Yumuk F., DANE F., ÖNEŞ T., Polat O., Madenci O. C., Demir G., et al.
BIOMARKERS, vol.18, no.1, pp.88-94, 2013 (SCI-Expanded)
- LXXI. Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer**
Turan N., BENEKLİ M., Koca D., Ustaalioglu B. O., DANE F., Ozdemir N., Ulas A., Oztup I., Gumus M., Ozturk M. A., et al.
ONCOLOGY, vol.84, no.1, pp.14-21, 2013 (SCI-Expanded)
- LXXII. FDG PET/CT Appearance of Portal Vein Tumor Thrombus in the Gastric Primitive Neuroectodermal Tumor Uncommon Primary Tumor Site With Rare Finding**
Aras M., DEDE F., DANE F., Aktas B., TUROĞLU H. T.
CLINICAL NUCLEAR MEDICINE, vol.38, no.1, pp.47-49, 2013 (SCI-Expanded)
- LXXIII. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience**
Cetin B., BENEKLİ M., DANE F., Boruban C., Gumus M., Oksuzoglu B., Kaplan M. A., Tufan G., Sevinc A., Coskun U., et al.
BREAST CARE, vol.8, no.1, pp.67-70, 2013 (SCI-Expanded)
- LXXIV. Low-Dose Docetaxel/Cisplatin - Leucovorin and 46 Hour Infusional Fluorouracil in Metastatic Gastric Carcinoma**
Alici S., Buyukberber S., Alkis N., BENEKLİ M., ÖZKAN M., Bilici A., Demirci U., Karaca H., Arpacı E., Gumus M., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.1, pp.423-427, 2013 (SCI-Expanded)
- LXXV. Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients**
Uncu D., Aksoy S., Cetin B., Yetisyigit T., Ozdemir N., Berk V., DANE F., Inal A., HARPUTLUOĞLU H., Budakoglu B., et al.
ONCOLOGY, vol.84, no.4, pp.240-245, 2013 (SCI-Expanded)
- LXXVI. Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial**
YALÇIN Ş., Uslu R., DANE F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., ŞENCAN O., Kilickap S., et al.
ONCOLOGY, vol.85, no.6, pp.328-335, 2013 (SCI-Expanded)
- LXXVII. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radiochemotherapy**
Kucukoner M., Arpacı E., Isikdogan A., Bilici M., Uncu D., Cetin B., Dane F., Inanc M., Ekinci A. S., Inal A., et al.
NEOPLASMA, vol.60, no.1, pp.19-25, 2013 (SCI-Expanded)
- LXXVIII. False Positive FDG PET/CT Resulting from Fibrous Dysplasia of the Bone in the Work-Up of a Patient with Bladder Cancer: Case Report and Review of the Literature**

- Aras M., ÖNEŞ T., DANE F., Noshari O., İNANIR S., ERDİL T. Y., TUROĞLU H. T.
IRANIAN JOURNAL OF RADIOLOGY, vol.10, no.1, pp.41-44, 2013 (SCI-Expanded)
- LXXIX. **Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers**
Baykara M., Buyukberber S., Ozturk B., Coskun U., Unsal D. K., Demirci U., DANE F., Kaplan M. A., BORA H., BENEKLİ M.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.4, pp.2557-2561, 2013 (SCI-Expanded)
- LXXX. **Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).**
Abulkhair O., Uslu R., Sezgin C., Bueyuekberber S., Darwish T., Isikdogan A., Gumus M., Dane F., Sevinc A., Halawani H., et al.
CANCER RESEARCH, vol.72, 2012 (SCI-Expanded)
- LXXXI. **Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience**
Cetin B., BENEKLİ M., Oksuzoglu B., Koral L., Ulas A., DANE F., Turker I., Kaplan M. A., Koca D., Boruban C., et al.
ONKOLOGIE, vol.35, no.12, pp.740-745, 2012 (SCI-Expanded)
- LXXXII. **Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer**
Yildiz R., BENEKLİ M., ÖZKAN M., Alkis N., Berk V., Kaplan M. A., Ciltas A., Karaca H., Durnali A. G., Coskun U., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.11, pp.1845-1852, 2012 (SCI-Expanded)
- LXXXIII. **SURVIVAL OUTCOMES OF GLIOBLASTOMA PATIENTS RECEIVED RADIOTHERAPY: BEFORE AND AFTER TEMOZOLAMIDE**
Atasoy B. M., Kefeli A. U., Seker A., Dane F., Yumuk F., Abacioglu U.
RADIOTHERAPY AND ONCOLOGY, vol.104, pp.35, 2012 (SCI-Expanded)
- LXXXIV. **The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens**
Kaya A. O., Coskun U., Gumus M., DANE F., ÖZKAN M., Isikdogan A., Alkis N., Buyukberber S., Yumuk F., Budakoglu B., et al.
JOURNAL OF CHEMOTHERAPY, vol.24, no.4, pp.217-220, 2012 (SCI-Expanded)
- LXXXV. **Tc-99m-MDP- and F-18-FDG-Avid Metastatic Liver Lesion The Similarities and Differences Between 2 Modalities**
Aras M., DEDE F., ÖNEŞ T., DANE F., İNANIR S., ERDİL T. Y., TUROĞLU H. T.
CLINICAL NUCLEAR MEDICINE, vol.37, no.4, pp.380-381, 2012 (SCI-Expanded)
- LXXXVI. **Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study**
Inal A., Kos F. T., Algin E., Yildiz R., Dikiltas M., Unek I. T., Colak D., Elkiran E. T., Helvacı K., Geredeli C., et al.
NEOPLASMA, vol.59, no.3, pp.297-301, 2012 (SCI-Expanded)
- LXXXVII. **Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience**
Ozkan M., Berk V., Kaplan M. A., Benekli M., Coskun U., Bilici A., Gumus M., Alkis N., Dane F., Ozdemir N. Y., et al.
NEOPLASMA, vol.59, no.1, pp.38-42, 2012 (SCI-Expanded)
- LXXXVIII. **The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy**
Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., Abacioglu U., Imeryuz N.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.269, no.1, pp.275-282, 2012 (SCI-Expanded)
- LXXXIX. **Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study**

Inal A., Kos F. T., Algin E., Yildiz R., Berk V., Unek I. T., Colak D., Kucukoner M., Elkiran E. T., Helvacı K., et al.
JOURNAL OF BUON, vol.17, no.1, pp.102-105, 2012 (SCI-Expanded)

- XC. **Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study**
Inal A., Ciltas A., Yildiz R., Berk V., Kos F. T., DANE F., Unek I. T., Colak D., Ozdemir N. Y., Buyukberber S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.5, pp.1841-1844, 2012 (SCI-Expanded)
- XCI. **5-Flourouracil-Induced Encephalopathy in Parkinson's Disease**
Korkmaz T., Seber S., Basaran G., YUMUK P. F., DANE F., Kocar M., Telli F., Turhal N. S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.51-53, 2012 (SCI-Expanded)
- XCII. **Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma**
Baykara M., Akkus M., Yildiz R., GÖNÜL İ. I., DURSUN A., Coskun U., BENEKLİ M., Sevinc A., DANE F., Buyukberber S.
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.11, no.12, pp.2227-2231, 2011 (SCI-Expanded)
- XCIII. **Is Subdivision of pT2 Tumors Superior to Lymph Node Metastasis for Predicting Survival of Patients with Gastric Cancer? Review of 224 Patients from Four Centers**
Bilici A., DANE F., Seker M., Ustaalioglu B. B. O., Aliustaoglu M., Temiz S., Gezen C., Yavuzer D., Aksu G., Mayadagli A., et al.
DIGESTIVE DISEASES AND SCIENCES, vol.56, no.11, pp.3226-3234, 2011 (SCI-Expanded)
- XCIV. **Malign epithelioid tumor at the site of an arteriovenous fistula in a dialysis patient**
Kahveci A., AŞICIOĞLU E., Arıkan H., DANE F., Aras M., SEÇKİN GENÇOSMANOĞLU D., Ozener C.
JOURNAL OF VASCULAR ACCESS, vol.12, no.4, pp.391, 2011 (SCI-Expanded)
- XCV. **FDG-PET/CT in Cancer Patients with Fibrous Dysplasia: Case Report and Review of The Literature**
Ones T., Aras M., Dane F., Dede F., Erdil T., Inanir S., Turoglu H.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- XCVI. **Clinical outcome of breast cancer patients with N3a (≥ 10 positive lymph nodes) disease: has it changed over years?**
Basaran G., Devrim C., Caglar H. B., Gulluoglu B., KAYA H., Seber S., Korkmaz T., Telli F., Kocak M., DANE F., et al.
MEDICAL ONCOLOGY, vol.28, no.3, pp.726-732, 2011 (SCI-Expanded)
- XCVII. **Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast**
Seker M., Bilici A., Ustaalioglu B. O., Yilmaz B., Ozturk B., ÜNAL A., DANE F., Ozdemir N. Y., Elkiran E. T., KALENDER M. E., et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.284, no.2, pp.405-409, 2011 (SCI-Expanded)
- XCVIII. **Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey**
Basaran G., Turhal N. S., Cabuk D., Yurt N., Yurtseven G., Gumus M., Teomete M., DANE F., YUMUK P. F.
MEDICAL ONCOLOGY, vol.28, no.2, pp.409-415, 2011 (SCI-Expanded)
- XCIX. **Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome**
Seber S., Basaran G., Korkmaz T., Telli F., Kocar M., Kanitez M., Dane F., Yumuk P. F., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- C. **The impact of bevacizumab usage on patients who were curative resected for liver-confined metastases from colorectal cancer**
Turan N., Koca D., Dane F., Ozdemir N., Ustaalioglu B. B. O., Oztup I., Ulas A., Berk V., Kucukoner M., Balakan O., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CI. **Adjuvant chemoradiotherapy in 450 patients with gastric cancer: The multicenter retrospective study.**
Kucukoner M., Isikdogan A., Bilici M., Tekin S. B., Uncu D., Cetin B., Dane F., Inanc M., Kaplan M. A., Cayir K., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CII. **Assessing cancer-related myths in relatives of cancer patients and the general public: A Turkish Oncology Group study**
Dane F., Turhal N. S., Unsal D., Sari S., Ulus C. U., Senturk N., Bingol D., Korkmaz T., Seber S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)

- CIII. **Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CIV. **Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of multicenter study**
Inal A., Isikdogan A., Kos T., Algin E., Gumus M., Dikilitas M., Elkiran E. T., Helvaci K., Geredeli C., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CV. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., Basaran G., Yumuk P. F., Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CVI. **Childhood, adolescents, and young adults (age 25 and younger) colorectal cancer: A multicenter study**
Kaplan M. A., Isikdogan A., Gumus M., Arslan U. Y., Geredeli C., Ozdemir N., Koca D., Dane F., Suner A., Elkiran E. T., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CVII. **Co-existence of Gastrointestinal Stromal Tumors with Other Primary Neoplasms**
Sevinc A., Seker M., Bilici A., Ozdemir N. Y., Yildiz R., Ustaalioglu B. O., KALENDER M. E., DANE F., Karaca H., Gemici C., et al.
HEPATO-GASTROENTEROLOGY, vol.58, no.107, pp.824-830, 2011 (SCI-Expanded)
- CVIII. **Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.**
Canhoroz M., Korkmaz T., Seber S., Bilici A., Okutur K., Toptas T., Basaran G., Dede F., Yumuk F., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CIX. **Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study**
Dane F., Ozturk M. A., Gumus M., Guven A., Aliustaoglu M., Cabuk D., Teomete M., Basaran G., Yumuk P. F., Turhal N. S.
JOURNAL OF BUON, vol.16, no.2, pp.257-264, 2011 (SCI-Expanded)
- CX. **Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer**
ATASOY B. M., DANE F., Kefeli A. U., Caglar H., Cingi A., Turhal N. S., Abacioglu U., Yegen C.
Turkish Journal of Gastroenterology, vol.22, no.1, pp.60-64, 2011 (SCI-Expanded)
- CXI. **A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer**
Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.4, 2011 (SCI-Expanded)
- CXII. **Primary breast mantle cell lymphoma with atypical relapse patterns**
DANE F., Seker M., YUMUK P. F., GÜNDÜZ F., Peker O., Basaran G., Turhal N. S.
JOURNAL OF BUON, vol.16, no.1, pp.181-182, 2011 (SCI-Expanded)
- CXIII. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
Yumuk P. F., Kefeli U., Ceyhan B., Dane F., Eroglu B. T., Gumus M., Cabuk D., Basaran G., Abacioglu U., Turhal N. S.
MEDICAL ONCOLOGY, vol.27, pp.1381-1388, 2010 (SCI-Expanded)
- CXIV. **ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study**
Turhal N. S., Bas E., Er O., Aliustaoglu M., Seber S., Dane F., Korkmaz T., Soyuer I., Ozkara S., Celikel Ç.
JOURNAL OF BUON, vol.15, no.4, pp.794-796, 2010 (SCI-Expanded)

- CXV. Prophylactic feeding with immune-enhanced diet ameliorates chemoradiation-induced gastrointestinal injury in rats**
 ATASOY B. M., Deniz M., DANE F., Ozen Z., Turan P., ERCAN F., Cerikcioglu N., ARAL C., Akgun Z., Abacioglu U., et al.
 INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, vol.86, no.10, pp.867-879, 2010 (SCI-Expanded)
- CXVI. Anxiety and depression in Turkish breast cancer patients**
 Turhal N. S., Dane F., Sinav H., Yalcin N., Khorshidi Z., Zeynep-Yalcin Z.
 JOURNAL OF BUON, vol.15, no.4, pp.720-725, 2010 (SCI-Expanded)
- CXVII. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience**
 Bilici A., Salepci T., DANE F., Gumus M., Ustaalioglu B. B. O., Seker M., Salman T., Turan C., Unal O., Yaylaci M.
 ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.282, no.4, pp.417-425, 2010 (SCI-Expanded)
- CXVIII. Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience**
 Ustaalioglu B. B. O., Gumus M., Bilici A., Seker M., DANE F., Salepci T., Salman T., Aliustaoglu M., Eser M., Gezen C., et al.
 MEDICAL ONCOLOGY, vol.27, no.2, pp.454-458, 2010 (SCI-Expanded)
- CXIX. A phase II pilot study of weekly docetaxel cisplatin and 5-fluorouracil in metastatic gastric cancer.**
 Okutur K., Dane F., Ilhan M., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Turhal N. S., Demir G.
 JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXX. The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAP-kinase, and phosphorylated P38 MAP-kinase in triple-negative breast cancers and their prognostic significance.**
 Yaman E., Gonul I. I., Buyukberber S., Coskun U., Yamac D., Sevinc A., Dane F., Uner A., Ozturk B., Kaya A. O.
 JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXI. The Association of Pre-treatment Peripheral Blood Markers with Survival in Patients with Pancreatic Cancer**
 Aliustaoglu M., Bilici A., Seker M., DANE F., Gocun M., Konya V., Ustaalioglu B. B. O., Gumus M.
 HEPATO-GASTROENTEROLOGY, vol.57, pp.640-645, 2010 (SCI-Expanded)
- CXXII. Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer**
 Kaya A. O., Buyukberber S., DANE F., Isikdogan A., Ustaalioglu B. O., Coskun U., YUMUK P. F., Dogu G. G., Ozdemir N. Y., Sevinc A., et al.
 TUMORI J, vol.96, no.3, pp.400-404, 2010 (SCI-Expanded)
- CXXIII. Evaluation of expression of ERCC1 in hepatocellular cancer**
 Bas E., Turhal N. S., Er O., Aliustaoglu M., Seber S., Dane F., Korkmaz T., Soyuer I., Ozkara S., Celikel Ç.
 JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXXIV. Cancer-related false knowledge in relatives of cancer patients and the general public**
 Turhal N. S., Dane F., Ulus C., Sari S., Senturk N., Bingol D.
 JOURNAL OF BUON, vol.15, no.2, pp.310-313, 2010 (SCI-Expanded)
- CXXV. Anthracycline-induced subclinical right ventricular dysfunction in adults**
 Ustaoglu M. A., Duman D., Gucun M., Konya V., Dane F., Gumus M.
 EUROPEAN HEART JOURNAL, vol.30, pp.569, 2009 (SCI-Expanded)
- CXXVI. Survivin in colorectal carcinoma: its role as a prognostic marker**
 Akif O. M., Dane F., Bas E., Ozkan N., Turhal S., Ataizi C. C.
 VIRCHOWS ARCHIV, vol.455, pp.125, 2009 (SCI-Expanded)
- CXXVII. Detection of human papillomavirus DNA by polymerase chain reaction and southern blot hybridization in colorectal cancer patients**
 Salepci T., Yazici H., Dane F., Topuz E., Dalay N., Onat H., Aykan F., Seker M., Aydinler A.
 JOURNAL OF BUON, vol.14, no.3, pp.495-499, 2009 (SCI-Expanded)
- CXXVIII. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature**
 Ozturk M. A., Dane F., Kaygusuz I., Asmaz O., Uzay A., Bayik M., Turhal N. S.
 JOURNAL OF BUON, vol.14, no.3, pp.511-514, 2009 (SCI-Expanded)

- CXXXIX. **A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion**
Dane F, Ozturk M. A., Tecimer T., Atasoy B. M., Cabuk D., Yumuk P. F., Basaran G., Teomete M., Turha N. S.
JOURNAL OF BUON, vol.14, no.2, pp.309-311, 2009 (SCI-Expanded)
- CXXX. **Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer**
Kefeli U, Dane F, Yumuk P. F., Karamanoglu A., Iyikesici S., Basaran G., Turhal N. S.
EUROPEAN JOURNAL OF CANCER CARE, vol.18, no.2, pp.191-194, 2009 (SCI-Expanded)
- CXXXI. **Vinorelbine in Combination with Carboplatin followed by Single-agent Consolidation Therapy for Unresectable Localized or Metastatic Non-small-cell Lung Carcinomas**
Alici S., Coskun U., Alkis N., Sevinc A., DANE F., Gumus M., ÖZKAN M., Kaya A. O., Celenkoglu G., Buyukberber S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.10, no.6, pp.1051-1055, 2009 (SCI-Expanded)
- CXXXII. **Preoperative radiotherapy with concomitant fluoropyrimidine-based chemotherapy for resectable locally advanced rectal cancer Rezekedilebilir lokal ileri evre rektum kanserinde floroprimidin bazli kemoterapi ile eş zamanli ameliyat öncesi radyoterapi**
ATASOY B. M., DANE F., Çağlar H., Tezcanli E., Cingi A., Abacioğlu U., Turhal S., Yeğen C.
Turk Onkoloji Dergisi, vol.23, no.4, pp.163-171, 2008 (SCI-Expanded)
- CXXXIII. **Does the standard test parameters for C-14 urea breath test really work in partially gastrectomised patients with gastric cancer**
Civen H., Dede F., Dane F., Ustaoglu M. A., Turhal S., Turoglu H. T., Inanir S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.35, 2008 (SCI-Expanded)
- CXXXIV. **Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk**
Tahan V., Canbakan B., BALCI H., DANE F., Akin H., Can G., Hatemi I., Olgac V., SONSUZ A., Ozbay G., et al.
HEPATO-GASTROENTEROLOGY, vol.55, no.85, pp.1433-1438, 2008 (SCI-Expanded)
- CXXXV. **Benefit from adjuvant anthracyclines according to hormone receptor status**
Basaran G. A., Cabuk D., Teomete M., Gulluoglu B., Kaya H., Dane F., Yumuk P. F., Turhal N. S.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- CXXXVI. **Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience**
Dane F., Gumus M., Ozturk M. A., Cabuk D., Atasoy M. B., Yumuk P. F., Basaran G., Iyikesici M. S., Teomete M., Abacioglu U., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- CXXXVII. **The markers of bone turnover in patients with lung cancer**
DANE F., Turk H. M., Sevinc A., Buyukberber S., Camci C., Tarakcioglu M.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, no.4, pp.425-428, 2008 (SCI-Expanded)
- CXXXVIII. **Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer**
Koldas M., Gumus M., Seker M., Seval H., Karaoglu H., DANE F., Kural A., Gumus A., Salepci T., Turhal N. S.
CLINICAL LUNG CANCER, vol.9, no.2, pp.112-115, 2008 (SCI-Expanded)
- CXXXIX. **Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma**
Atasoy B. M., Dane F., Yumuk R., Akguen Z., Turhal N. S., Abacioglu U., Sengoez M.
JOURNAL OF BUON, vol.13, no.1, pp.43-50, 2008 (SCI-Expanded)
- CXL. **Impact of body mass index on cancer development**
YUMUK P. F., Dane F., Yumuk V. D., Yazici D., Ege B., Bekiroglu N., Toprak A., Iyikesici S., Basaran G., Turhal N. S.
JOURNAL OF BUON, vol.13, no.1, pp.55-59, 2008 (SCI-Expanded)
- CXLI. **Clinicopathologic features of dual chronic hepatitis B and C infection: A comparison with single hepatitis B, C and delta infections**
Senturk H., Tahan V., Canbakan B., Dane F., Ulger Y., Ozaras R., Tabak F., Mert A., Ozbay G.
ANNALS OF HEPATOLOGY, vol.7, no.1, pp.52-58, 2008 (SCI-Expanded)
- CXLII. **FDG-PET scan in colorectal cancer**
DANE F., DEDE F., ATASOY B. M.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.18, no.2, pp.121-128, 2008 (SCI-Expanded)

CXLIII. Clinical outcome of node-negative (NN) breast cancer (BC) patients

Basaran G. A., Cabuk D., Dane F., Teomete M., Iyikesici S., Meltem E., Gulluoglu B., Kaya H., Abacioglu U., Yumuk F., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)

CXLIV. Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital

Dane F., Gumus M., Ozturk A., Yumuk F., Iyikesici S., Basaran G., Cabuk D., Teomete M., Turhal N. S.

JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)

CXLV. The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma

Gumus M., Dane F., Kaya S., Ozturk M. A., Yumuk P. F., Atasoy B. M., Basaran G., Salepci T., Yaylaci M., Turhal N. S.

JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)

CXLVI. Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C

Tahan V., Tahan G., DANE F., Uraz S., Yardim M.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.16, no.2, pp.224-225, 2007 (SCI-Expanded)

CXLVII. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival

Cabuk D., Basaran G., Celikel C., Dane F., Yumuk P. F., Iyikesici M. S., Ekenel M., Turhal N. S.

ONCOLOGY, vol.72, pp.111-117, 2007 (SCI-Expanded)

CXLVIII. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples

Gumus M., Yumuk P. F., Salepci T., Aliustaoglu M., Dane F., Ekenel M., Basaran G., Kaya H., Barisik N., Turhal N. S.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.25, no.4, pp.515-521, 2006 (SCI-Expanded)

CXLIX. What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery?

Gumus M., Yumuk P. F., Atalay G., Aliustaoglu M., Macunluoglu B., Dane F., Caglar H., Sengoz M., Turhal S.

TUMORI J, vol.91, no.2, pp.168-172, 2005 (SCI-Expanded)

CL. Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk P. F., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.20, no.1, pp.76, 2005 (SCI-Expanded)

CLI. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients

Yumuk P. F., Aydin S., Dane F., Gumus M., Ekenel M., Aliustaoglu M., Karamanoglu A., Sengoz M., Turhal S.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.19, no.6, pp.609-610, 2004 (SCI-Expanded)

CLII. 99m-Tc-MDP-scintimammography in the evaluation of breast masses or tumor angiogenesis

Turhal N., Dane F., Dede F., Gumus M., Yumuk P. F., Cakalagaoglu F., Savci D., Karaman M., Gulluoglu B., Turoglu H.

ANTICANCER RESEARCH, vol.24, no.3B, pp.1999-2006, 2004 (SCI-Expanded)

CLIII. Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee

Iyikesici S., Turhal N. S., YUMUK P. F., DANE F., Gumus M., Basaran G., Ekenel M., Avery B.

ANNALS OF ONCOLOGY, vol.15, pp.195-196, 2004 (SCI-Expanded)

CLIV. Clinical features and adjuvant treatment outcomes of colon cancer (cc) in two outpatient populations of Knoxville, Tennessee and Istanbul, Turkey

DANE F., Turhal N. S., Iyikesici S., Gumus M., YUMUK P. F., Basaran G., Ekenel M., Avery B.

ANNALS OF ONCOLOGY, vol.15, pp.95, 2004 (SCI-Expanded)

CLV. Causes and risk factors for liver injury following bone marrow transplantation

Ozdogan O. C., Ratip S., Al Ahdab Y., Dane F., Al Ahdab H., Imeryuz N., Tozun N.

JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.36, no.5, pp.421-426, 2003 (SCI-Expanded)

Articles Published in Other Journals

- I. **The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer**
KOCA S., BABACAN N. A., ÖKTEN İ. N., TELLİ T. A., ALAN Ö., Aktas B., DANE F., YUMUK P. F.
Eurasian Journal of Medical Investigation, vol.7, no.2, pp.170-174, 2023 (Peer-Reviewed Journal)
- II. **Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib**
DEMİRCAN N. C., ENGÜR C. Ö., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., ARIKAN R., YASAR A., CELEBI A., ALAN O., ISIK S., ÖZGÜVEN S., et al.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, no.4, pp.379-387, 2022 (ESCI)
- III. **Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment –Single-Center Experience**
ERCELEP Ö., AKIN TELLİ T., ALAN Ö., Hasanov R., Şimşek E. T., Babacan N., Kaya S., KAYA H., DANE F., YUMUK P. F.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.35, no.3, pp.334-339, 2020 (ESCI)
- IV. **Evaluating the frequency of outpatient visits of cancer patients during the remission period**
KANİTEZ M., BEŞİROĞLU M., TELLİ F., DANE F., YUMUK P. F., TURHAL N. S.
Journal of Family Medicine & Community Health, vol.2, no.1, pp.1025, 2015 (Peer-Reviewed Journal)
- V. **Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)**
İNAL A., KOS F. T., ALGİN E., YILDIZ R., BERK V., UNEK İ. T., COLAK D., DANE F., GEREDELİ C., ISIKDOĞAN A.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.19, no.2, pp.125-129, 2015 (ESCI)
- VI. **What to expect from HER-2 directed therapies in advanced gastric cancer?**
DANE F.
MARMARA MEDICAL JOURNAL, vol.28, no.4, pp.11-15, 2015 (ESCI)
- VII. **Prognostic role of initial PET CT SUV max value in metastatic gastric adenocarcinoma**
KORKMAZ T., ŞEBER E. S., OKUTUR S. K., CANHOROZ M., BİLİCİ A., TOPTAŞ T., BAŞARAN G., DEDE F., YUMUK P. F., DANE F., et al.
Mediterranean Oncology Journal, vol.1, no.2, pp.35-39, 2012 (Peer-Reviewed Journal)
- VIII. **Interdisciplinary collaboration in management of nutrition during chemoradiotherapy in cancer patients: A pilot study** **Kanser hastalarında kemoradyoterapi sırasında beslenme yönetiminde disiplinler arası işbirliğinin yeri: Bir pilot çalışma**
ATASOY B. M., DANE F., KUŞCU M. K., ALSAN ÇETİN İ., ÖZGEN Z., YÜKSEK KANTAŞ Ö., DEMİREL B., AKSU A., İBRAHİMOV R., ABACIOĞLU U.
Marmara Medical Journal, vol.25, no.1, pp.32-36, 2012 (Scopus)
- IX. **Efforts to Validate the Applicability of Established Chemotherapy Treatment in Turkish Cancer Patients**
TURHAL N. S., DANE F., TEZCAN S., KOÇAK M., TELLİ F., KANİTEZ M., ŞEBER E. S., AKTAŞ B., YUMUK P. F.
pharmaceutica Analytica Acta, vol.14, pp.1-4, 2011 (Peer-Reviewed Journal)
- X. **Chemoradiotherapy Experience In Locally Advanced Esophageal Cancer**
ALSAN ÇETİN İ., YUMUK P. F., ATASOY B. M., DANE F., BATİREL H. F., ÇAĞLAR H. B., İBRAHİMOV R., ABACIOĞLU U.
MARMARA MEDICAL JOURNAL, 2011 (Scopus)
- XI. **Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi**
ATASOY B. M., DANE F., SARI M., YUMUK P. F., AKGÜN ÇETİNKAYA Z., TURHAL N. S., ABACIOĞLU U., ŞENGÖZ K. M.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.23, pp.1-11, 2008 (Scopus)
- XII. **Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer**
ATASOY B. M., ABACIOĞLU U., DANE F., ÖZGEN Z., YUMUK P. F., ÖZDEN S., AKGÜN Z., MAYADAGLI A., BAŞARAN G., TURHAL S., et al.
Journal of B.U.ON., vol.12, no.2, pp.203-208, 2007 (Scopus)
- XIII. **Lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri hastalarının değerlendirilmesi, Marmara Üniversitesi deneyimi**

YUMUK P. F., İYİKESİCİ M. S., GÜMÜŞ M., Aliustaoğlu M., DANE F., BAŞARAN G., EKENEL M., ABACIOĞLU U., TURHAL N. S.

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.19, pp.106-110, 2004 (ESCI)

XIV. **Evre 1 (T1 N0 M0) Meme Kanseri: Patolojik özellikler ve klinik sonuçlar**

BAŞARAN G., EKENEL M., Demirkalem P., Çakır T., GÜLLÜOĞLU M. B., GÜMÜŞ M., DANE F., İYİKESİCİ M. S., KAYA H., YUMUK P. F., et al.

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.19, pp.53-57, 2004 (ESCI)

XV. **Evre I (T1N0M0) meme kanseri: patolojik özellikler ve klinik sonuçlar.**

başaran g., ekenel m., demirkalem p., çakır t., GÜLLÜOĞLU M. B., GÜMÜŞ M., DANE F., İYİKESİCİ M. S., KAYA H., YUMUK P. F., et al.

Türk Onkoloji Dergisi, vol.19, no.2, pp.53-57, 2004 (ESCI)

Books & Book Chapters

I. **Nötropenik Ateş**

DANE F., YUMUK P. F., ODABAŞI Z.

in: Acil Hastaya Yaklaşım, Dahiliye, Yavuz DG, Mülazımoğlu L, Editor, Marmara Üniversitesi Tıp Fakültesi Yayını, İstanbul, pp.163-171, 2009

II. **Maliniteye Bağlı Hiperkalsemi**

YUMUK P. F., DANE F.

in: Acil Hastaya Yaklaşım, Dahiliye, Yavuz DG, Mülazımoğlu L, Editor, Marmara Üniversitesi Tıp Fakültesi Yayını, İstanbul, pp.160-162, 2009

III. **Melanom aşıları**

YUMUK P. F., DANE F.

in: Melanom: Tanı-Tedavi-Takip, Gökhan DEMİR, Editor, Güneş Tıp Kitabevi, İstanbul, pp.117-125, 2009

IV. **Onkolojik Aciller**

YUMUK P. F., DANE F.

in: Acil Hastaya Yaklaşım, Dahiliye, Yavuz DG, Mülazımoğlu L, Editor, Marmara Üniversitesi Tıp Fakültesi Yayını, İstanbul, pp.172-178, 2009

Refereed Congress / Symposium Publications in Proceedings

I. **Multicenter real life experience of biological agents in patients with metastatic colorectal cancer**

Demirci U., Erturk I., Arslan C., Bilici A., Cevik D., Cicin I., Dane F., Dolek B., Kaplan M., Karadurmus N., et al.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31

II. **Does insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?**

Alan O., AKIN TELLİ T., Aktas B., KOCA S., ÖKTEN İ. N., BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., Ercelep O., UĞURLU M. Ü., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 10 - 14 December 2019, vol.80

III. **S 033: Survival Data and Prognostic Factors in HER2/Neu Positive Metastatic Breast Cancer Patients Undergoing TDM1: A Single Center Experience**

ARIKAN R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.

3rd National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019

IV. **Multiple Primary Tumors: Single Center Experience**

BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM and 3rd International Congress on Oncological Sciences (ICONS), Antalya, Turkey, 27 November - 01 December 2019, vol.5, pp.1

V. **Metastatik Akciğer Adenokanserinde Osimertinib Kullanımı: Tek MerkezDeneyimi**

- BAŞOĞLU TÜYLÜ T., ARIKAN R., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
Kanserde Güncel Gelişmeler 2019 Akciğer Kanseri Sempozyumu, Turkey, 22 - 23 November 2019
- VI. **SS 12: Metastatik Akciğer Adenokanserinde Osimertinib Kullanımı: Tek Merkez Deneyimi**
BAŞOĞLU TÜYLÜ T., ARIKAN R., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
Kanser Güncel Akciğer Kanseri Sempozyumu, Turkey, 22 - 23 November 2019
- VII. **SS 104: İlerlemiş Mesane Kanseri Prognostik Faktörler**
ALACA TOPÇU Z., ÖZTÜRK M. A., YILDIRIM M. E., ARIKAN R., BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
14. Üroonkoloji Kongresi, Turkey, 6 - 10 November 2019
- VIII. **Survival Data and Prognostic Factors in HER2/Neu Positive Metastatic Breast Cancer Patients Undergoing TDM1: A Single Center Experience**
ARIKAN R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
3th National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019
- IX. **S 031: Prognostic Value of GRIm Scores in Pancreatic Cancer**
BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., AKIN TELLİ T., ERCELEP Ö., BABACAN N. A., DANE F., YUMUK P. F.
3rd National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019
- X. **NADIR VAKA: MESANENİN MÜSİNÖZ ADENOKANSERİ**
BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ALAN Ö., ARIKAN R., ERCELEP Ö., KAYA S., BABACAN N., FİLİNTE D., DANE F., YUMUK P. F.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019
- XI. **ONKOTÜRK KAYIT SİSTEMİ: SOLİD ORGANMALİGNİTELİ HASTALARDA TEDAVİ VE İZLEM TERCİHLERİNİN BELİRLENMESİNE YÖNELİK KAYIT ÇALIŞMASI ARA DEĞERLENDİRME SONUÇLARI**
ALAN Ö., YUMUK P. F., DANE F., BABACAN N., ÇOŞKUN H. Ş., SEZGİN GÖKSU S., ÇELİK İ., OYAN ULUÇ B., YÜCEL İ.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019
- XII. **PALATIN TONSİL METASTAZ! YAPMIŞ PRİMER AKCİĞER PLEOMORFİK SARKOMU, OLGU SUNUMU**
ARIKAN R., ALAN Ö., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., ERCELEP Ö., KAYA S., BABACAN N., DANE F., YUMUK P. F.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019
- XIII. **Evaluation of Efficacy, Safety Data and relapse Pattern of Definitive Chemoradiotherapy in Non-Small Cell Lung Cancer Single Center Experience**
ERCELEP Ö., ALAN Ö., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., BABACAN N., KAYA S., DANE F., ADLI M., YUMUK P. F.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, vol.2, pp.21
- XIV. **Liver Metastases: Case Discussion**
DULUNDU E., YEGEN Ş. C., DANE F., YENER N., DOKDOK M., DAGOĞLU N.
Anadolu Medical Center Meeting Program 28-29 September 2018, İstanbul, Turkey, 28 - 29 September 2018
- XV. **Analysis of feasibility of geriatric assessment tools in elderly cancer patients and effects on anti-cancer treatment planning**
Günaydın U. M., Tufan Çiçin A., Günaydın Ş., DANE F., BABACAN N. A., ÖZTÜRK M. A., YUMUK P. F.
2018 ASCO Annual Meeting, Illinois, United States Of America, 1 - 05 June 2018, vol.36
- XVI. **MARMARA ÜNİVERSİTESİ ,RETROSPEKTİF MALİGN MELANOM VERİLERİ**
BABACAN N., ALAN Ö., ERCELEP Ö., KAYA S., HASANOV R., AKIN TELLİ T., ŞALVA H., ÖZTÜRK M. A., DANE F., YUMUK P. F.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018
- XVII. **LOKAL İLERİ MEME KANSERİ HASTALARINDA SERUM DR -70 ELİZA DÜZEYLERİ**
KOCA S., AKTAŞ B., BEŞİROĞLU M., ALAN Ö., AKIN TELLİ T., BABACAN N., DANE F., YUMUK P. F.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018
- XVIII. **A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal C., Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36
- XIX. **Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer**

treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

Yalcin S, Dane F, Oksuzoglu B, Yildirim N, Isikdogan A, Ozkan M, Demirag G, Coskun H. S., Karabulut B, Evrensel T., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36

- XX. **Pankreasın Primer Skuamöz Hücreli Karsinomu Olgu Sunumu**
KORUK K., ALAN Ö., YUMUK P. F., DANE F.
Marmara Üniversitesi Tıp Fakültesi 6. İç Hastalıkları Mezuniyet Sonrası Eğitim Kursu, İstanbul, Turkey, 12 - 13 January 2018
- XXI. **A retrospective review of small cell lung cancer (SCLC) patients treated at Marmara University Hospital.**
ERİŞ A., ÖZTÜRK M. A., DANE F., BOZKURLAR E., KOCAKAYA D., ALAN O., HASANOV R., AKIN TELLİ T., HALİL S., TANRIKULU ŞİMŞEK E., et al.
IASLC18th World Conference on Lung Cancer, 15 - 18 October 2017, pp.570
- XXII. **Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer**
Demirelli B., Babacan N., Koca S., Uzun B. N., Ercelep O., Ozturk M. A., Kaya S., Simsek E. T., Khalil S., Hasanov R., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- XXIII. **Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA).**
Ozaslan E., Ozkan M., Cicin I., Benekli M., Kocer M., Uysal M., Oksuzoglu B., Isikdogan A., Cubukcu E., Elkiran E. T., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XXIV. **Analysis of survival and prognostic factors in metastatic colorectal cancer patients treated with first line bevacizumab.**
Demircan N., Dane F., Ozturk M. A., Besiroglu M., Babacan N., Kaya S., Ercelep O., Simsek E. T., Halil S., Koca S., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XXV. **EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.**
Gumus M., Geredeli C., Ucar M., Kaya S., Demir H., Unal O. U., Degirmenci M., Dogu G. G., Turan N., Yildirim N., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XXVI. **Kolorektal kanserde metastatik hastalığın erken döneminde yapılan karaciğere yönelik lokal tedavi sağ kalımı iyileştirir**
Totama A., ÖZTÜRK M. A., DANE F., YEGEN Ş. C., BALTACIOĞLU F., ÖNEŞ T., Ercelep Ö., Kaya S., Babacan N. A., YUMUK P. F.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XXVII. **Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study**
Artac M., Korkmaz L., Coskun H., Dane F., Karabulut B., Karaagac M., Cabuk D., Karabulut S., Aykan F., Doruk H., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- XXVIII. **A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).**
Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., Mertsoylu H., Artac M., Camci C., Karabulut B., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34
- XXIX. **Does responses in PET CT correlates with pathological complete response after neoadjuvant chemotherapy in locally advanced breast cancer**
Kaya S., Tanrikulu Simsek E., Uğurlu M. Ü., Ozgen Z., Halil S., Besiroglu M., Koca S., Babacan N., Dane F., Kaya H., et al.

25th annual ASCO meeting, Illinois, United States Of America, 29 May - 02 June 2015

- XXX. **Turkish National Gastric Cancer Registry.**
Buyukberber S., Dumanli E., Uncu D., Ozkan M., Uslu R., Dogu G. G., Kara O., Abali H., Turna H., Ozturk B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXI. **Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.**
Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., Can A., Dane F., Babacan T., Oksuzoglu B.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXII. **Do responses in PET/CT correlate with pathological complete response after neoadjuvant chemotherapy in locally advanced breast cancer?**
Kaya S., Simsek E. T., Ugurlu U., Ozgen Z., Halil S., Besiroglu M., Koca S., Babacan N., Dane F., Kaya H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXIII. **What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study.**
Kaplan M. A., Urakci Z., Gumus M., Arslan U. Y., Geredeli C., Ozdemir N., Koca D., Oruc Z., Uysal M., Dane F., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXIV. **Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.**
Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., Harputluoglu H., Oksuzoglu B., Kucukoner M., Ozdemir N., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXV. **Turkish National Colon Cancer Registry.**
Benekli M., Dumanli E., Kilickap S., Uncu D., Aliustaoglu M., Cicin I., Gumus M., Ozkan M., Kocer M., Karaoglu A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXVI. **Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study).**
Gumus M., Dane F., Karabulut B., Uygun K., Aydin K., Orhan B., Oksuzoglu B., Tarhan O., Buyukberber S., Okutur K., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXVII. **Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry**
Ciltas A., Karaca M., Uncu D., Ozkan M., Aliustaoglu M., Tekin S. B., Cicin I., Kocer M., Dane F., Oksuzoglu B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXVIII. **The prognostic value of lymph node ratio in patients with curatively resected pancreatic adenocarcinoma.**

Turan N., Araz M., Algin E., Unal O. U., Benekli M., Tastekin D., Dane F., Unek T., Eren T., Turkmen E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- XXXIX. **Kastrasyona dirençli metastatik prostat kanserinde abirateron kullanan hasta sonuçlarımız**
HALİL S., BEŞİROĞLU M., KOCA S., TANIDIR Y., TUNCER Ç., KAYA S., ŞİMŞEK E. T., ALSAN ÇETİN İ., BABACAN N., DANE F., et al.
21. ulusal kanser kongresi, Turkey, 22 - 26 April 2015
- XL. **NEOADJUVAN KEMOTERAPİ VERİLEN LOKAL İLERİ EVRE MEME KANSERLİ HASTALARIN GENEL KAREKTERİSTİK ÖZELLİKLERİNİN İNCELENMESİ**
Kaya S., Tanrikulu Şimşek E., Uğurlu M. Ü., Özgen Z., Köse H., Halil S., Beşiroğlu M., Koca S., Babacan N., Dane F., et al.
21. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 22 - 26 April 2015, pp.628
- XLI. **LOKAL İLERİ MEME KANSERİNDE NEOADJUVAN KEMOTERAPİYE CEVABI GÖSTERMEDE PET BT NİN ROLÜ VE PATOLOJİK TAM CEVAPLA UYUMU**
Kaya S., Tanrikulu Şimşek E., Uğurlu M. Ü., Özgen Z., Köse H., Halil S., Beşiroğlu M., Koca S., Babacan N., Dane F., et al.
21. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 22 - 26 April 2015, pp.604
- XLII. **Efficacy of second line bevacizumab and irinotecan treatment in high grade glioma**
BEŞİROĞLU M., TANRIKULU ŞİMŞEK E., Halil S., Kaya S., DANE F., BOZKURT S., ATASOY B. M., EKİNCİ G., ZİYAL M. İ., YUMUK P. F.
Trends in Central Nervous System Malignancies, EORTC EANO ESMO Conference 2015, 27 - 28 March 2015
- XLIII. **GRAD III ANAPLASTİK GLİAL TÜMÖR TANILI HASTALARDA RADYOTERAPİYLE EŞ ZAMANLI ADJUVAN TEMOZOLAMİD SONUÇLARI TEK MERKEZ DENEYİMİ**
Sahibov E., Atasoy B. M., Şeker A., Özgen Z., Dane F., Ziyal M. İ., Abacıoğlu U.
VII. MULTİDİSİPLİNER NÖROONKOLOJİ SEMPOZYUMU, İstanbul, Turkey, 23 - 25 May 2014, vol.46
- XLIV. **Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue.**
Demirci A., Alkis N., Dane F., Yazilitas D., Durnali A., Inanc M., Ozcelik M., Akman T., Yazici O. K., Kaplan M. A., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XLV. **The clinical and pathologic characteristics of 400 gastrointestinal stromal tumor patients from Turkey: The final results of the Turkish Anatolian Society of Medical Oncology Multicenter Registry**
Sevinc A., Seker M., Yildiz R., Cihan S., Kaplan M. A., Dane F., Karaca H., Uyeturk U., Bilicli A., Ozdemir N., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XLVI. **KEMORADYOTERAPİ SONRASI GEÇ DÖNEM BÖBREK HASARI TOLERANS DOZLAR ÜZERİNE KLİNİK FONKSİYONEL VE DOZİMETRİK BİR İNCELEME**
İbrahimov R., Dede F., Özen Z., Arıkan İ. H., Özgen Z., Dane F., Atasoy B. M.
XI. ULUSAL RADYASYON ONKOLOJİ KONGRESİ, Antalya, Turkey, 23 - 27 April 2014, vol.29, pp.96
- XLVII. **BENEFICIAL EFFECT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS**
Kani H. T., Siykhymbayev A., Demircan N., Banzragch M., Yegin E. G., Bicakci E., Aydin Y., Irmak R., Duman D. G., Yumuk P. F., et al.
49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, London, Canada, 9 - 13 April 2014, vol.60
- XLVIII. **Clinical significance of HER2 overexpression in gastric and gastro-esophageal junction cancers: Is there any discordance between IHC and FISH**
Baykara M., Benekli M., Ekinci O., Irkkan C., Demirci U., Karaca H., Unal O. U., Dane F., Akinci B., Turkoz F. P.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- XLIX. **The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival**

Cetin B., Tastekin D., Aktas B., Guler T., Kaplan M. A., Berk V., Gumusay O., Dane F., Ozkan M., Benekli M.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September
- 01 October 2013, vol.49

- L. **The prognostic impact of survivin and REG1A in diffuse large B-cell lymphoma**
Seker M., Gumus M., Barisik N. O., Dane F., Bozkurt S. U., Bilici A., Seber S., Mayadagli A., YUMUK P. F., Turhal S.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September
- 01 October 2013, vol.49
- LI. **The evaluation of factors predicting recurrence and prognosis for patients with node-negative gastric cancer after curative resection**
Bilici A., Selcukbiricik F., Ustaalioglu B. B., Seker M., Dane F., Aliustaoglu M., Gumus M., Demirelli F.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September
- 01 October 2013, vol.49
- LII. **Interim results of observational study to determine K-ras mutation rates in patients with metastatic colorectal cancer in Turkey (TURKRAS study)**
Gumus M., Dane F., Karabulut B., Uygun K., Orhan B., Aydin K., Buyukberber S., Okutur S. K., Unek T., Ozen R. S.
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September
- 01 October 2013, vol.49
- LIII. **Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.**
Turan N., Dane F., Unal O. U., Benekli M., Kara H. V., Koca D., Balvan O., Eren T., Tastekin D., Dogan E., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31
- LIV. **Prognostic significance of presence of any mucinous component in curatively resected stage II and III colorectal cancer patients who received adjuvant treatments: Data from a single tertiary center.**
Dane F., Ozturk M. A., Yumuk P. F., Kocar M., Besiroglu M., Atasoy B. M., Telli F., Kanitez M., Aktas B., Turhal N. S.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31
- LV. **Retrospective analysis of 178 patients with stage I rectum cancer.**
Cihan S., Ozdemir N., Urakci Z., Kucukoner M., Dane F., Yazilitas D., Durnali A., Yuksel S., Colak D., Seker M., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31
- LVI. **The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience.**
Yildiz R., Buyukberber S., Koca D., Korai L., Ciltas A., Unal O. U., Gumus M., Ozdemir N., Dane F., Berk V., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31
May - 04 June 2013, vol.31
- LVII. **PET CT after breast conserving surgery**
ÖZGÜVEN S., İNANIR S., UĞURLU M. Ü., GÜLLÜOĞLU M. B., DANE F., ÖNEŞ T., DEDE F., ERDİL T. Y., TUROĞLU H. T.
Annual congress of the EANM 2012, 27 - 31 October 2012
- LVIII. **Esansiyel trombositoz tanılı hastada gelişen diffüz büyük B hücreli non Hodgkin lenfoma**
İLHAN B., TOPTAŞ T., AKTAŞ B., AŞKAN G., DANE F., BOZKURT S., ATAGÜNDÜZ İ., ADIGÜZEL C., TUĞLULAR A. T.
38. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2012
- LIX. **PET/CT after Breast Conserving Surgery in Breast Cancer**
Ozguven S., Inanir S., Ugurlu U., Gulluoglu B., Dane F., Ones T., Dede F., Erdil T., Turoglu H.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October
2012, vol.39
- LX. **Prognostic factors in development of brain metastasis in stage III non small cell cancer patients after definitive treatment**
ALSAN ÇETİN İ., AKGÜN Z., YUMUK P. F., DANE F., KARAÜÇ G., SÜNNETÇİ N., TURHAL S., ATASOY B. M.
ESMO, 28 September - 02 October 2012
- LXI. **THE PROGNOSTIC SIGNIFICANCE OF TYMIDINE KINASE ACTIVITY LEVELS IN METASTATIC**

COLORECTAL CANCER

Seber E. S., Korkmaz T., Okutur K., Dane F., Yumuk P. F., Aktas B., Kanitez M., Demir G., Turhal S. N.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.217

LXII. PROGNOSTIC FACTORS IN DEVELOPMENT OF BRAIN METASTASIS IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS AFTER DEFINITIVE TREATMENT

Cetin I. A., Cetinkaya Z. A., Yumuk P. F., Dane F., Karauc G., Sunnetci N., Turhal N. S., Atasoy B. M.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.394

LXIII. PROGNOSTIC SIGNIFICANCE OF COMBINED POSITIVITY OF LYMPHATIC, VASCULAR, AND PERINEURAL INVASION (TRIPLE POSITIVE) IN STAGE II/III COLORECTAL CANCER; A NEW PARADIGM WORTH TO INVESTIGATE?

Dane F., Ozturk M. A., Kocar M., Atasoy B. M., Aktas B., Telli F., Kanitez M., Besiroglu M., Yumuk P. F., Turhal S. N.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.186

LXIV. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

DANE F., ATASOY B. M., Akgün Çetinkaya Z., YUMUK P. F., ÇABUK D., Teomete M., BAŞARAN G., TURHAL N. S., ABACIOĞLU U.

JOURNAL OF CLINICAL ONCOLOGY, Chicago, 1 - 06 June 2012, vol.30

LXV. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LXVI. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

Dane F., Atasoy B. M., Akgun Z., Yumuk F., Cabuk D., Teomete M., Basaran G., Turhal S., Abacioglu U.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LXVII. Prognostic analysis of the patients with operable gastric cancer and the importance of tolerability of therapy: Study of Anatolian Society of Medical Oncology

Kucukoner M., Arpacı E., Isikdogan A., Bilici M., Uncu D., Cetin B., Dane F., Cayir K., Inanc M., Ekinci A. S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LXVIII. Evre III Küçük hücreli akciğer kanseri tanısıyla küratif tedavi uygulanan hastalarda beyin metastazını gelişimini etkileyen faktörler

ALSAN ÇETİN İ., akgün çetinkaya z., YUMUK P. F., DANE F., karaüç g., sünnetçi n., ATASOY B. M.

Ulusal torasik maliniteleri kongresi, Turkey, 10 - 13 May 2012

LXIX. REKTUM KANSERİNİN ADJUVAN TEDAVİSİNDE ORAL FLOROPİRİMİDİN FOLİNİK ASİTLE EŞ ZAMANLI RADYOTERAPİ UYGULAMASININ YAŞAM KALİTESİNE ETKİSİ

Özgen Z., Dane F., Özden S., Akgün Z., Atasoy B. M., Yumuk P. F., Mayadağlı A., Turhal S., Abacioğlu U.

X. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Antalya, Turkey, 19 - 23 April 2012, pp.244

LXX. NÜKS YÜKSEK GRADLI GLİAL TÜMÖRLERDE BEVASİZUMABIN SAĞKALIM ÜZERİNE ETKİSİ

Dane F., Atasoy B. M., Aktaş B., Özgen Z., Alsan Çetin İ., Abacioğlu U., Yumuk P. F.

X. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Antalya, Turkey, 19 - 23 April 2012, pp.187-188

LXXI. KANSER TANISI ALAN HASTALARDA POLİKLİNİK ŞARTLARINDA ÜÇ FARKLI TEST İLE NÜTRİSYONEL DURUM DEĞERLENDİRMESİ

Atasoy B. M., Aygör H. A., Günaydın D., Özlen T., İbrahimov R., Özgen Z., Dane F., Yumuk P. F.

X. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Antalya, Turkey, 19 - 23 April 2012, pp.112-113

- LXXII. **Evre III küçük hücreli dışı akciğer kanseri tanısıyla küratif tedavi uygulanan hastalarda beyin metastazı gelişimini etkileyen faktörler**
KARAÜÇ G., ALSAN ÇETİN İ., AKGÜN Z., YUMUK P. F., DANE F., SÜNNETÇİ N., ATASOY B. M.
Marmara Üniversitesi tıp fakültesi 7. araştırma günleri, Turkey, 18 - 20 April 2012
- LXXIII. **Lokal ileri evre mesane kanserinde haftalık düşük doz gemsitabinle eş zamanlı definitif kemoradyoterapi**
ATASOY B. M., DANE F., ALSAN ÇETİN İ., ÜÇÜNCÜ KEFELİ A., İBRAHİMOV R., TURHAL S., ABACIOĞLU U., TÜRKERİ L.
10. Üroonkoloji kongresi, Turkey, 26 - 30 October 2011
- LXXIV. **EGFR and KRAS Gene Mutations in Lung Adenocarcinomas and Their Associations With Smoking in Turkish Patients**
Mert A. G., Yumuk P. F., Ozturk M. A., Dane F., Evman S., Yuksel M., Celikel Ç., Kucukodaci Z., Baloglu H., Turhal N. S.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXV. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
KORKMAZ T., ŞEBER E. S., BAŞARAN G., YUMUK P. F., DANE F., OKUTUR S. K., Kanitez M., Koçar M., Telli F., DEMİR O. G., et al.
47th American Society of Clinical Oncology (ASCO) Annual Meeting, 3 - 07 June 2011
- LXXVI. **Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome**
ŞEBER E. S., BAŞARAN G., KORKMAZ T., Telli F., Koçar M., Kanitez M., DANE F., YUMUK P. F., TURHAL N. S.
47th American Society of Clinical Oncology (ASCO) Annual Meeting, 3 - 07 June 2011
- LXXVII. **THE IMPRESSION WE GIVE TO PATIENTS WHEN BREAKING BAD NEWS: A MULTICENTER STUDY IN A TURKISH CANCER POPULATION**
Yaman E., Yamac D., Turhal S., Karaca B., Coskun H. S., Komurcu S., Yavuzsen T., Dane F., Nalca M., Akmansu M.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.368-369
- LXXVIII. **Tolerability of anthracyclines in Turkish breast cancer patients**
TURHAL N. S., DANE F., ŞEBER E. S., KORKMAZ T., YUMUK P. F., Kanitez M., Telli F., Koçar M., BAŞARAN G.
8th BUON Congress, 8 - 11 September 2010
- LXXIX. **Clinical, pathological factors predicting early relapse in hormone receptor positive early breast cancer**
BAŞARAN G., ÇABUK D., KORKMAZ T., Koçar M., Telli F., DANE F., YUMUK P. F., TURHAL N. S.
8th BUON Congress, 8 - 11 September 2010
- LXXX. **Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience**
Cabuk D., Basaran G., Korkmaz T., Seber S., DANE F., Telli F., Yumuk F., Turhal N. S.
European Breast Cancer Conference, Barcelona, Spain, 24 March 2010, vol.8, pp.205
- LXXXI. **COEXISTENCE OF GASTROINTESTINAL STROMAL TUMORS WITH OTHER NEOPLASMS**
Seker M., Sevinc A., Bilici A., Ozdemir N., Yildiz R., Kalender M., Ustaalioglu B., Dane F., Uncu D., Gemici C., et al.
12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 30 June - 03 July 2010, vol.21, pp.57
- LXXXII. **Factors affecting type of surgical treatment in patients with breast cancer**
Garip M., Gumus M., Dane F., Seker M., Bilici A., Ustaalioglu B. O., Salman T., Sonmez B., Salepci T., Yaylaci M.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- LXXXIII. **Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)**
Yumuk P. F., Teomete M., Dane F., Cabuk D., Basaran G., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- LXXXIV. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**

Kefeli U., Yumuk P. F., Ceyhan B., Dane F., Eroglu B., Cabuk D., Basaran G., Teomete M., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

- LXXXV. **Challenges in applicability of Standard treatment for head and neck cancer patients in Istanbul**
TURHAL N. S., DANE F., ŞEBER E. S., KORKMAZ T., ÇABUK D., BAŞARAN G., YUMUK P. F., ÖZKÖK H. B., ATASOY B. M.
Euroasian Congress on Head Neck Oncology, 27 - 28 April 2009
- LXXXVI. **Platinum plus vinorelbine (VNR) on days 1 and 8 in advanced non-small cell lung Cancer: Single center results**
YUMUK P. F., Teomete M., DANE F., ÇABUK D., BAŞARAN G., TURHAL N. S.
7th Congress of Balkan Union of Oncology (BUON), 15 - 19 October 2008
- LXXXVII. **Survival and prognostic features of stage II and III Rectal Cancer (RC) in Turkish patients population**
DANE F., ÖZTÜRK M. A., GÜMÜŞ M., YUMUK P. F., BAŞARAN G., TURHAL N. S.
7th Congress of Balkan Union of Oncology (BUON), 15 - 19 October 2008
- LXXXVIII. **Clinical/pathological characteristics of breast cancer (BC) patients (pts) with triple-negative (TN) tumors**
ÇABUK D., BAŞARAN G., Teomete M., DANE F., YUMUK P. F., TURHAL N. S.
7th Congress of Balkan Union of Oncology BUON, 15 - 19 October 2008
- LXXXIX. **Prognostic factors and treatment outcomes in patients with metastatic colorectal cancer (CRC)**
DANE F., GÜMÜŞ M., ÇABUK D., Teomete M., YUMUK P. F., TURHAL N. S.
7th Congress of Balkan Union of Oncology (BUON), 15 - 19 October 2008
- XC. **Demographical Survival and Prognostic Features of Resected Rectal Cancer in Turkish Patients Population**
DANE F., GÜMÜŞ M., Yaman E., ÖZTÜRK M. A., SEVİNÇ A., ATASOY B. M., ÇABUK D., İYİKESİCİ M. S., YUMUK P. F., BAŞARAN G., et al.
18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, 8 - 11 October 2008, vol.55, pp.28
- XCI. **Benefit from adjuvant anthracyclines according to hormone receptor status**
BAŞARAN G., ÇABUK D., Teomete M., GÜLLÜOĞLU M. B., KAYA H., DANE F., YUMUK P. F., TURHAL N. S.
44th American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May - 03 June 2008, vol.26
- XCII. **Clinical outcome of triple-negative (TN) breast cancer (BC)**
ÇABUK D., BAŞARAN G., KAYA H., GÜLLÜOĞLU M. B., Teomete M., DANE F., YUMUK P. F., TURHAL N. S.
44th American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May - 03 June 2008
- XCIII. **Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: single institution experience**
DANE F., GÜMÜŞ M., ÖZTÜRK M. A., ÇABUK D., ATASOY B. M., YUMUK P. F., BAŞARAN G., İYİKESİCİ M. S., Teomete M., ABACIOĞLU U., et al.
44th American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May - 03 June 2008
- XCIV. **cerrahi sonrası üç kez lokal nüks yapan bartolin bezi adenoid kistik karsinom vakasının radyoterapi uygulaması ve başarılı lokal kontrolü**
ALSAN ÇETİN İ., DANE F., EREN Ş. F., ŞENGÖZ K. M., ABACIOĞLU U.
VIII:Ulusal radyasyon onkolojisi kongresi, Turkey, 19 - 23 April 2008
- XCv. **Anal kanserlerde definitif tedavi sonuçlarımız**
AKGÜN Z., ATASOY B. M., ÇAĞLAR H., ALSAN ÇETİN İ., DANE F., ABACIOĞLU U.
VIII:Ulusal radyasyon onkolojisi kongresi, Turkey, 18 - 23 April 2008
- XCVI. **Evre III kuratif tedavi uygulanmış küçük hücre dışı akciğer kanseri hastalarında beyin metastazı oluşumunu etkileyen faktörler**
AKGÜN Z., ÇAĞLAR H., ATASOY B. M., ALSAN ÇETİN İ., DANE F., ABACIOĞLU U.
3. Ulusal Torosik onkoloji kongresi, Turkey, 21 - 24 June 2007
- XCvII. **Outcome of patients with stage 3 and 4 non-small cell lung cancer in Marmara University Hospital**
YUMUK P. F., Teomete M., DANE F., ÇABUK D., ÖZKÖK H. B., ABACIOĞLU U., BAŞARAN G., TURHAL N. S.

12th World Conference on Lung Cancer J Thorac Oncol, 2 - 06 September 2007, vol.2

- XCVIII. **The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma**
GÜMÜŞ M., DANE F., Kaya S., ÖZTÜRK M. A., YUMUK P. F., ATASOY B. M., BAŞARAN G., Salepçi T., Yaylacı M., TURHAL N. S.
JOURNAL OF CLINICAL ONCOLOGY, 1 - 05 June 2007, vol.25
- XCIX. **Clinical outcome of node-negative (NN) breast cancer (BC) patients**
BAŞARAN G., ÇABUK D., DANE F., Teomete M., İYİKESİCİ M. S., EKENEL M., GÜLLÜOĞLU M. B., KAYA H., ABACIOĞLU U., YUMUK P. F., et al.
JOURNAL OF CLINICAL ONCOLOGY, 31 May - 05 June 2007, vol.25, pp.11102
- C. **Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital**
DANE F., GÜMÜŞ M., ÖZTÜRK M. A., YUMUK P. F., İYİKESİCİ M. S., BAŞARAN G., ÇABUK D., Teomete M., TURHAL N. S.
JOURNAL OF CLINICAL ONCOLOGY, 31 May - 05 June 2007, vol.25
- CI. **Primer serviks kanser tanılı hastaların kemoradyoterapi sonuçları**
ALSAN ÇETİN İ., AKGÜN Z., YUMUK P. F., DANE F., ATASOY B. M., ABACIOĞLU U.
XVII.Ulusal kanser kongresi, Turkey, 19 - 23 April 2007
- CII. **Radyoterapi ile eş zamanlı ve adjuvan temozolomid kullanılan glioblastoma multiforme tanılı hastalarda tedavi sonuçları**
AKGÜN Z., ATASOY B. M., ALSAN ÇETİN İ., DANE F., YUMUK P. F., ABACIOĞLU U.
XVII.Ulusal kanser kongresi, Turkey, 19 - 23 April 2007
- CIII. **Assessment of toxicity and the factors limiting concomitant radiochemotherapy in squamous cell carcinoma of head and neck (HNSCC)**
Atasoy B. M., Dane F., Ozen Z., Akgun Z., Yumuk F., Abacioglu U.
International Meeting on Innovative Approaches in Head and Neck Oncology, Barcelona, Spain, 22 - 27 February 2007, vol.82
- CIV. **Concurrent administration of urasil-tegafur and folinic acid with radiation for locally advanced rectum cancer: Tolerability and quality of life assessments**
Atasoy B. M., Abacioglu U., Ozgen Z., Dane F., Yumuk F. P., Akgun Z., Ozden S., Mayadagli A., Turhal N. S., Sengoz M.
Conference of the Spanish-Portuguese-and -Latin-American-Association, Leipzig, Germany, 09 October 2006, vol.81
- CV. **Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey**
Teomete M., YUMUK P. F., İYİKESİCİ M. S., DANE F., BAŞARAN G., ÇABUK D., ÖZKÖK H. B., ABACIOĞLU U., TURHAL N. S.
ANNALS OF ONCOLOGY, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225-226
- CVI. **Outcome of unresectable locally advanced and/or metastatic colorectal cancer patients receiving systemic chemotherapy**
DANE F., YUMUK P. F., GÜMÜŞ M., İYİKESİCİ M. S., TUFAN ÇİNÇİN A., BAŞARAN G., ÇABUK D., ÖZTÜRK M. A., Erdem R., Teomete M., et al.
6th Congress of Balkan Union of Oncology (BUON), 12 - 15 September 2006, pp.64
- CVII. **Concomitant administration of urasil-tegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectal cancer: Tolerability assessment,**
ATASOY B. M., ABACIOĞLU U., Özgen Z., DANE F., YUMUK P. F., Akgün Çetinkaya Z., Özden S., MAYADAĞLI A., TURHAL N. S.
6th Congress of Balkan Union of Oncology (BUON), 12 - 15 September 2006
- CVIII. **Outcome of Rectal Carcinoma Patients receiving adjuvant Chemoradiotherapy**
DANE F., GÜMÜŞ M., İYİKESİCİ M. S., YUMUK P. F., BAŞARAN G., ÖZTÜRK M. A., ATASOY B. M., ABACIOĞLU U., ÇABUK D., Teomete M., et al.
6th Congress of Balkan Union of Oncology (BUON), 12 - 15 September 2006
- CIX. **Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital**
DANE F., GÜMÜŞ M., İYİKESİCİ M. S., YUMUK P. F., BAŞARAN G., ATASOY B. M., ABACIOĞLU U., ÇABUK D., Teomete

M., TURHAL N. S.

42nd American Society of Clinical Oncology (ASCO) Annual Meeting, 2 - 06 June 2006, vol.24

- CX. **Tolerability assessment of urasil-tegafur (UFT)/folinic acid (FA) as concurrent chemoradiation (CRT) in adjuvant rectal cancer treatment**
ATASOY B. M., ABACIOĞLU U., Özgen Z., DANE F., YUMUK P. F., Akgün Çetinkaya Z., Özden S., MAYADAĞLI A., TURHAL N. S., ŞENGÖZ K. M.
42nd American Society of Clinical Oncology (ASCO) Annual Meeting, 2 - 06 June 2006, vol.24
- CXI. **REKTUM KANSERİNİN ADJUVAN TEDAVİSİNDE RADYOTERAPİYLE EŞ ZAMANLI TEGAFUR URASİL UFT FOLİNİK ASİT FA UYGULAMASI TOLERABİLİTE DEĞERLENDİRMESİ**
Atasoy B. M., Abacıoğlu U., Özgen Z., Dane F., Yumuk P. F., Mayadağlı A., Turhal S., Şengöz K. M.
VİULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Muğla, Turkey, 19 - 23 April 2006, pp.70
- CXII. **Prolonged interval in Prophylactic Heparin Flushing for Maintenance Subcutaneous Implanted Port Care in Patients with Cancer**
KEFELİ U., Karamanoğlu A., DANE F., YUMUK P. F., İYİKESİCİ M. S., BAŞARAN G., TURHAL N. S.
17th International Congress on Anti-Cancer Treatment, 29 January - 02 February 2006, pp.348
- CXIII. **Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience**
Cabuk D., Basaran G., Iyikesici S., Ekenel M., Dane F., Teomete M., Gumus M., Aliustaoglu M., Yumuk F., Turhal S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.109
- CXIV. **Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, İstanbul, Turkey**
Teomete M., Yumuk P. F., Iyikesici M. S., Dane F., Basaran G., Cabuk D., Caglar H. B., Abacioglu U., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225-226
- CXV. **Adjuvant concomitant administration of urasil-tegafur (UFT) and folinic acid (FA) during irradiation for locally advanced rectum cancer: Tolerability assessment**
Atasoy B. M., Abacioglu U., Ozgen Z., Dane F., Yumuk P. F., Akgun Z., Ozden S., Mayadagli A., Turhal N. S., Sengoz M.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.134
- CXVI. **Outcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital**
Dane F., Yumuk F., Gumus M., Iyikesici S., Tufan A., Basaran G., Cabuk D., Teomete M., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.129
- CXVII. **Stage I (T1N0M0) breast cancer (BC): Pathological characteristics and clinical outcome**
Basaran G. A., Cabuk D., Caglar H. B., Iyikesici S., Tebessum C., Gulluoglu B., Kaya H., Dane F., Yumuk P. F., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.113
- CXVIII. **Association between presence of HPV DNA and P53 in breast cancer patients**
Yumuk P. F., Gumus M., Kaya H., Alam K., Dane F., Gulluoglu B., Salepci T., Barisik N., Basaran G., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.110-111
- CXIX. **Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital**
Dane F., Gumus M., Yumuk P. F., Iyikesici S., Ozturk A., Basaran G., Caglar H. B., Cabuk D., Teomete M., Turhal N. S.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.130
- CXX. **Interstitial pneumonitis associated with docetaxel administration**
Dane F., Topaloglu N., Abul Y., Yumuk P. F., Turhal N. S., Ceyhan B., Celikel T., Caglar H., Basaran G., Ahiskali R.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006,

vol.17, pp.307

- CXXI. **Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital**
İYİKESİCİ M. S., YUMUK P. F., DANE F., EKENEL M., BAŞARAN G., TURHAL N. S.
LUNG CANCER, Barcelona, Spain, 3 - 06 July 2005, vol.49, pp.249
- CXXII. **küçük hücreli dışı akciğer kanseri evre III tanısıyla küratif tedavi uygulanan hastalarda beyin metastazı gelişimini etkileyen faktörler**
KARAÜÇ G., ALSAN ÇETİN İ., AKGÜN Z., YUMUK P. F., DANE F., SÜNNETÇİ N., ATASOY B. M.
Ulusal toraks maliniteleri kongresi, Turkey, 10 - 13 May 2012
- CXXIII. **Outcome of adjuvant treatment in elderly Turkish breast cancer patients.**
Ekenel M., Basaran G., Dane F., Iyikesici S., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXXIV. **VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.**
Cabuk D., Basaran G., Yumuk P. F., Celikel Ç., Dane F., Iyikesici M., Ekenel M., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXXV. **Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.**
Basaran G., Dane F., Iyikesici S., Ekenel M., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXXVI. **Outcome of elderly patients with advanced non-small cell lung cancer.**
Gumus M., Palak B., Iyikesici S., Yumuk P. F., Seker M., Topal A., Dane F., Salepci T., Yayla A., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXXVII. **The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).**
Iyikesici M., Kefeli U., Basaran G., Dane F., Ekenel M., Yumuk P. F., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- CXXVIII. **The impact of body mass index on cancer: A Hospital-based study**
YUMUK P. F., YUMUK V. D., YAZICI D., Ege B., BEKİROĞLU G. N., DANE F., İYİKESİCİ M. S., BAŞARAN G., TURHAL N. S.
14th European Congress on obesity, Atina, Greece, 1 - 04 June 2005, vol.6, pp.82
- CXXIX. **mid e adenokarsinomlarında cerrahi rezeksiyon sonrasında adjuvan kemoradyoterapi sonuçlarımız**
AKGÜN Z., ALSAN ÇETİN İ., KARAÜÇ G., ÇAĞLAR H., ABACIOĞLU U., DANE F., YUMUK P. F., ŞENGÖZ K. M., TURHAL S.
XVI: Ulusal kanser kongresi, Turkey, 20 - 24 April 2005
- CXXX. **Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease**
BAŞARAN G., EKENEL M., Demirkalem P., Çakır K., GÜLLÜOĞLU M. B., GÜMÜŞ M., DANE F., İYİKESİCİ M. S., YUMUK P. F., TURHAL N. S.
ANNALS OF ONCOLOGY, 29 October - 02 November 2004, vol.15, pp.68
- CXXXI. **Clinical features and adjuvant treatment outcomes of colon cancer in two outpatient populations of Knoxville Tennessee and Istanbul Turkey**
DANE F., TURHAL N. S., İYİKESİCİ M. S., GÜMÜŞ M., YUMUK P. F., BAŞARAN G., EKENEL M., Avery B.
Ann Oncol ESMO 2004, 28 October - 02 November 2004
- CXXXII. **Treatment outcomes in non-small cell lung cancer patients: Comparison between Marmara University, Istanbul Turkey and Knoxville Tennessee**
İYİKESİCİ M. S., TURHAL N. S., YUMUK P. F., DANE F., GÜMÜŞ M., BAŞARAN G., EKENEL M., Avery B.
Ann Oncol ESMO 2004, Viyana, 28 October - 02 November 2004
- CXXXIII. **Human papilloma virus: Is it a new etiological factor in breast cancer?**
Gumus M., Yumuk F., Salepci T., Aliustacglu M., Ekenel M., Basaran G., Dane F., Kaya H., Barisik N., Turhal N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

- CXXXIV. **FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.**
Dane F., Yumuk P. F., Turhal N., Ekenel M., Basaran G., Iyikesici M., Tecimer C.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- CXXXV. **Is the incidence of anal canal cancers different in Moslem societies?**
Cabuk D., Yumuk P. F., Abacioglu U., Demir G., Dane F., Gumus M., Ozguroglu M., Ekenel M., Basaran G., Turhal N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- CXXXVI. **Mantle cell lymphoma presenting as a breast mass**
GÜNDÜZ F., YUMUK P. F., DANE F., PEKER Ö., EKENEL M., İYİKESİCİ M. S., BAŞARAN G., TURHAL N. S.
15th Int. Congress on Anti-Cancer Treatment, Paris, France, 31 January - 03 February 2004
- CXXXVII. **Adjuvant treatment outcome of high risk stage II and stage III colon cancer patients treated in Marmara University, Istanbul**
DANE F., İYİKESİCİ M. S., GÜMÜŞ M., YUMUK P. F., EKENEL M., BAŞARAN G., Karamanoğlu A., TURHAL N. S.
15th Int. Congress on Anti-Cancer Treatment, 31 January - 03 February 2004
- CXXXVIII. **Correlation between Tc-99m MDP uptake and prognostic factors in breast cancer**
DANE F., TURHAL N. S., GÜMÜŞ M., DEDE F., Çakalağaoğlu F., YUMUK P. F., TUROĞLU H. T.
5th Int. Congress of Nuclear Oncology and 15th National Congress of Turkish Society of Nuclear Medicine, 1 - 05 May 2002
- CXXXIX. **Tc-99m MDP scintimammography in the detection of breast lesions**
DANE F., TURHAL N. S., GÜMÜŞ M., DEDE F., ŞENGÖZ K. M., YUMUK P. F., TUROĞLU H. T.
5th Int. Congress of Nuclear Oncology and 15th National Congress of Turkish Society of Nuclear Medicine, 1 - 05 May 2002, pp.47

Metrics

Publication: 314

Citation (WoS): 1151

Citation (Scopus): 729

H-Index (WoS): 16

H-Index (Scopus): 15